Antithrombotic therapy in patients with acute and chronic ischemic stroke

Abstract

For antithrombotic therapy in ischemic stroke patients, selection of an appropriate drug based on early diagnosis of stroke subtype is important especially in the acute phase. In addition, it is necessary to consider the effect of reducing cardiovascular disease including stroke recurrence, and the risk of increasing hemorrhagic complications. The balance of the risk–benefit greatly changes between the acute phase and the chronic phase.